The clinical pharmacology of antiretrovirals in development

Bibliography

• GAZZARD B: British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). HIV Med. (2005) 6(Suppl.2):1-61.
   PubMed Web of Science ®Google Scholar
• BLANCO J, BARRETINA J, CLOTET B, ESTE JA: R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism. J. Leukoc. Biol. (2004) 76(4):804-811.
   PubMed Web of Science ®Google Scholar
• LAZZARIN A: Enfuvirtide: the first HIV fusion inhibitor. Expert Opin. Pharmacother. (2005) 6(3):453-464.
   PubMed Web of Science ®Google Scholar
• KUMAR S, KWEI GY, POON GK etal.: Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein. J. Pharmacol. Exp. Ther. (2003) 304(3):1161-1171.
   PubMed Web of Science ®Google Scholar
• MOYLE G, LALEZARI J: Aplaviroc clinical development suspended and vicriviroc naive study stopped by DSMB. The Journal of Viral Entry (2005) 1(2):47.
   Google Scholar
• ABEL S, VAN DER RYST E, MUIRHEAD GJ etal.: Pharmacokinetics of single and multiple oral doses of UK-427,857 a novel CCR5 antagonist in healthy volunteers. 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA (2003):abstract 547.
   Google Scholar
• SPARKS S, ADKISON K, SHACHOY-CLARK A, PISCITELLI S, DEMAREST J: Prolonged duration of CCR5 occupancy by 873140 in HIV-negative and HIV-positive subjects. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA (2005):abstract 77.
   Google Scholar
• FATKENHEUER G, POZNIAK AL, JOHNSON M etal.: Evaluation of dosing frequency and food effect on viral load reduction during short-term monotherapy with UK-427,857, a novel CCR5 antagonist. 15th International AIDS Conference. Bangkok, Thailand (2004):abstract TuPeB4489.
   Google Scholar
• DEMAREST J, ADKISON K, SPARKS S etal.: Single and multiple dose escalation study to investigate the safety, pharmacokinetics, and receptor binding of GW873140, a novel CCR5 receptor antagonist, in healthy subjects. 11th Conference on Retroviruses and Opportunistic Infections. San Fransisco, CA, USA (2004):abstract 139.
   Google Scholar
• ADKISON K, LOU Y, FANG L etal.: Pharmacokinetic/pharmacodynamic (PK/PD) relationships of the novel CCR5 antagonist, 873140, during a 10-day monotherapy study in HIV-infected subjects. 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec City, Canada (2005):abstract 77.
   Google Scholar
• ADKISON KK, SHACHOY-CLARK A, FANG L etal.: Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects. Antimicrob. Agents Chemother. (2005) 49(7):2802-2806.
   PubMed Web of Science ®Google Scholar
• PISCITELLI SC, GALLICANO KD: Interactions among drugs for HIV and opportunistic infections. N. Engl. J. Med. (2001) 344(13):984-996.
   PubMed Web of Science ®Google Scholar
• ABEL S, RUSSELL D, RIDGWAY C, MUIRHEAD G: Overview of the drugdrug interaction data for maraviroc (UK-427,857). 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec City, Canada (2005):abstract 76.
   Google Scholar
• MUIRHEAD G, POZNIAK AL, GAZZARD B etal.: A novel probe drug interaction study to investigate the effect of selected ARV combinations on the pharmacokinetics of a single oral dose of UK-427,857 in HIV +ve subjects. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA (2005):abstract 663.
   Google Scholar
• ABEL S, TAYLOR-WORTH R, RIDGWAY C, WEISSGERBER G, KRAFT M: Effect of boosted tipranavir on the pharmacokinetics of maraviroc (UK 427,857) in healthy volunteers. 10th European AIDS Conference. Dublin, Ireland (2005):LBPE4.3/15.
   Google Scholar
• SANSONE A, GUILLAUME M, KRAANM etal.: The pharmacokinetics of SCH-417690 when administered alone and in combination with lamivudine/zidovudine. 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec City, Canada (2005):abstract 84.
   Google Scholar
• SANSONE A, GUILLAUME M, KRAANM etal.: Pharmacokinetics of SCH-417690 administered alone and in combination with tenofovir. 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec City, Canada (2005):abstract 85.
   Google Scholar
• SALTZMAN M, ROSENBERG M, KRAAN M etal.: Pharmacokinetics of SCH-417690 administered alone or in combination with ritonavir and efavirenz in healthy volunteers. 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil (2005):abstract TuPe3.1B08.
   Google Scholar
• SANSONE A, SALTZMAN M, ROSENBERG M etal.: Pharmacokinetics of SCH-417690 administered alone or in combination with ritonavir and efavirenz in healthy volunteers. 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec City, Canada (2005):abstract 79.
   Google Scholar
• SANSONE A, SEIBERLING M, KRAANM, KEUNG A, MARTINHO M: Similar increase in SCH-417690 plasma exposure with coadministration of varying doses of ritonavir in healthy volunteers. 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec City, Canada (2005):abstract 78.
   Google Scholar
• SANSONE A, SALTZMAN M, ROSENBERG M etal.: Pharmacokinetics of SCH-417690 administered alone or in combination with ritonavir or lopinavir/ritonavir. 6th International Workshop on Clinical Pharmacology of HIV Therapy. Qubec City, Canada (2005):abstract 83.
   Google Scholar
• ADKISON K, SHACHOY-CLARK A, FANG YL L etal.: The pharmacokinetic interaction between the CCR5 antagonist 873140 and lopinavir/ritonavir in healthy subjects. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA (2005):abstract 664.
   Google Scholar
• GELEZIUNAS R, GALLAGHER K, ZHANG H etal.: HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor -d-2,3-dideoxy-2,3-didehydro-5-fluorocytidine (Reverset). Antivir. Chem. Chemother. (2003) 14(1):49-59.
   PubMedGoogle Scholar
• MURPHY RL, SCHRMANN D, BEARD A etal.: Tolerance and potent anti-HIV-1 activity of reverset following 10 days of mono-therapy in treatment-nave individuals. 11th Conference on Retroviruses and Opportunistic Infections. San Fransisco, CA, USA ( 2003):abstract 137.
   Google Scholar
• MURPHY RL, SCHRMANN D, BEARD A etal.: Potent anti-HIV-1 activity of Reverset following 10 days of monotherapy in treatment-nave individuals. 15th International AIDS Conference. Bangkok, Thailand (2004):abstract MoOrB1056.
   Google Scholar
• COHEN C, KATLAMA C, MURPHY R etal.: Antiretroviral activity and tolerability of reverset (D-d4FC), a new fluorocytidine nucleoside analog, when used in combination therapy in treatment-experienced patients: results of Phase IIb study RVT-203. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janerio, Brazil (2005):abstract WeOaLB0103.
   Google Scholar
• ANDRIES K, AZIJN H, THIELEMANST etal.: TMC-125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. (2004) 48(12):4680-4686.
   PubMed Web of Science ®Google Scholar
• GRUZDEV B, RAKHMANOVA A, DOUBOVSKAYA E etal.: A randomized, double-blind, placebo-controlled trial of TMC-125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. Aids (2003) 17(17):2487-2494.
   PubMed Web of Science ®Google Scholar
• GAZZARD BG, POZNIAK AL, ROSENBAUM W etal.: An open-label assessment of TMC-125 a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. Aids (2003) 17(18):F49-F54.
   PubMed Web of Science ®Google Scholar
• PISCITELLI S, BAEDE P, DEDIER G, VANT KLOOSTER N, GRAHAM N: Pharmacokinetics of TMC-125 in HIV infected patients and healthy volunteers. 3rd International Workshop on Clinical Pharmacology of HIV Therapy. Washington, DC, USA (2002):abstract 6.1.
   Google Scholar
• BAEDE P, PISCITELLI S, GRAHAM N, VANT KLOOSTER GA: Drug Interactions with TMC-125, a potent next generation non-nucleoside reverse transcriptase inhibitor. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (2002):A-1827.
   Google Scholar
• PISCITELLI S, BAEDE P, VANT KLOOSTER GA, GRAHAM N: TMC-125, a potent next generation nnrti, does not alter lopinavir/ritonavir pharmacokinetics in healthy volunteers. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (2002):A-1824.
   Google Scholar
• SCHOLLER M, HOETELMANS R, BOLLEN S etal.: No significant interaction between TMC-125 and didanosine (DDI) in healthy volunteers. 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec City, Canada (2005):poster 2.22.
   Google Scholar
• SCHOLLER M, HOETELMANS R, BEETS G etal.: Substantial improvement of oral bioavailability of TMC-125 using new tablet formulations in healthy volunteers. 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec City, Canada (2005):poster 6.8.
   Google Scholar
• GOEBEL F, YAKOVLEV A, POZNIAK A etal.: TMC-278: potent anti-HIV activity in antiretroviral therapy-nave patients. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA (2005):abstract 160.
   Google Scholar
• HOETELMANS R, KESTENS D, MARIEN K etal.: Effect of food and multiple-dose pharmacokinetics of TMC-278 as an oral tablet formulation. 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec City, Canada (2005):poster 6.9.
   Google Scholar
• HOETELMANS R, KESTENS D, STEVENS M etal.: Pharmacokinetic interaction between the novel non-nucleoside reverse transcriptase inhbitior (NNRTI) TMC-278 and tenofovir disoproxil fumarate (TDF) in healthy volunteers. 6th Inernational Workshop on Clinical Pharmacology of HIV Therapy. Quebec City, Canada (2005):poster 2.11.
   Google Scholar
• HOETELMANS R, VAN HEESWIJK R, KESTENS D etal.: Pharmacokinetic interaction between TMC-278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) and lopinavir/ritonavir (LPV/r) in healthy volunteers. 10th European AIDS Conference. Dublin, Ireland (2005):PE 4.3/1.
   Google Scholar
• DE MEYER S, AZIJN H, SURLERAUX D etal.: TMC-114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob. Agents Chemother. (2005) 49(6):2314-2321.
   PubMed Web of Science ®Google Scholar
• KING NM, PRABU-JEYABALAN M, NALIVAIKA EA etal.: Structural and thermodynamic basis for the binding of TMC-114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J. Virol. (2004) 78(21):12012-12021.
   PubMed Web of Science ®Google Scholar
• HOETELMANS R, VAN DER SANDT I, DE PAUW M etal.: TMC-114, a next generation HIV protease inhibitor: pharmacokinetics and safety following oral administration of multiple doses with and without low doses of ritonavir in healthy volunteers. 10th Conference on Retroviruses and Opportunistic Infections. Boston, NE, USA (2003):abstract 549.
   Google Scholar
• HOETELMANS R, LEFEBVRE E, VANDER SANDT I etal.: Pharmacokinetics and effect of food on TMC-114, a potent next generation protease inhibitor, boosted with low-dose ritonavir. 5th International Workshop on Clinical Pharmacology of HIV Therapy. Rome, Italy (2004):abstract 5.6.
   Google Scholar
• SEKAR V, KESTENS D, SPINOSA-GUZMAN S etal.: The effects of different meal types on the pharmacokinetics of TMC-114 tablet formulation dosed with ritonavir in healthy volunteers. 10th European AIDS Conference. Dublin, Ireland (2005):PE4.1/1.
   Google Scholar
• WINSTON A, BOFFITO M: The management of HIV-1 protease inhibitor pharmacokinetic interactions. J. Antimicrob. Chemother. (2005) 56(1):1-5.
   PubMed Web of Science ®Google Scholar
• SEKAR V, HOETELMANS R, DEMAREZ T etal.: Pharmacokinetics of TMC114: effect of omeprazole and ranitidine. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil (2005):abstract WePe3.3C13.
   Google Scholar
• HOETELMANS R, MARIEN K, DEPAUW M etal.: Pharmacokinetic interaction between TMC-114/ritonavir (RTV) and tenofovir in healthy volunteers. XVth World AIDS Conference. Bangkok, Thailand (2004).
   Google Scholar
• SEKAR V, DE MAREZ T, GUZMAN S etal.: Pharmacokinetic interaction between TMC-114/ritonavir and atazanavir in healthy volunteers. 10th European AIDS Conference. Dublin, Ireland (2005):PE4.3/4.
   Google Scholar
• HOETELMANS R, LASURE A, KOESTER A etal.: The effect of TMC-114, a potent next-generation hiv protease inhibitor, with low-dose ritonavir on atorvastatin pharmacokinetics. 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
   Google Scholar
• HAZEN R, STCLAIR M, HANLON M etal.: GW-0385, a broadspectrum, ultrapotent inhibitor of wild-type and protease-inhibitor-resistant HIV-1. 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France (2003):abstract 541.
   Google Scholar
• REDDY S, FORD SL, STEIN DS etal.: Single-dose safety and pharmacokinetics (PK) of GW-640385X (385): an HIV-1 protease inhibitor (PI). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2003):A-1800.
   Google Scholar
• FORD SL, SHELTON MJ, MURRAY SC etal.: A study to investigate the interaction between 640385/ritonavir (640385/r) and tenofovir (TDF) in healthy subjects. 45th International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2005):presentation number: A-1198.
   Google Scholar
• NAIR V: Novel inhibitors of HIV integrase: the discovery of potential anti-HIV therapeutic agents. Curr. Pharm. Des. (2003) 9(31):2553-2565.
   PubMed Web of Science ®Google Scholar
• GRATTON S, CHEYNIER R, DUMAURIER MJ, OKSENHENDLERE, WAIN-HOBSON S: Highly restricted spread of HIV-1 and multiply infected cells within splenic germinal centers. Proc. Natl. Acad. Sci. USA (2000) 97(26):14566-14571.
   PubMed Web of Science ®Google Scholar
• MORALES-RAMIREZ JO, TEPPLER H, KOVACS C etal.: Antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, in ART-naive HIV infected patients. 10th European AIDS Conference. Dublin, Ireland (2005).
   Google Scholar
• GRINSZTEJN B, NGUYEN BY, KATLAMA C etal.: Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA (2006):abstract 159LB.
   Google Scholar
• DUPUIS ML, CIANFRIGLIA M, COSTIR etal.: HIV-1 integrase inhibitors are potent substrates for the MDR1 multi-drug transporter. 13 Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA (2006):abstract 566.
   Google Scholar
• KAWAGUCHI I, ISHIKAWA T, ISHIBASHI M, IRIE S, KAKEE A: Safety and pharmacokinetics of single oral dose of JTK-303/GS-9137, a novel HIV integrase inhibitor, in healthy volunteers. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA (2006):abstract 580.
   Google Scholar
• DEJESUS E, BERGER D, MARKOWITZM etal.: The HIV integrase inhibitor GS-9137 (JTK-303) exhibits potent antiviral activity in treatment-nave and experienced patients. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA (2006):abstract 160LB.
   Google Scholar
• KAPLAN AH, ZACK JA, KNIGGE M etal.: Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J. Virol. (1993) 67(7):4050-4055.
   PubMed Web of Science ®Google Scholar
• LI F, GOILA-GAUR R, SALZWEDEL K etal.: PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc. Natl. Acad. Sci. USA (2003) 100(23):13555-13560.
   PubMed Web of Science ®Google Scholar
• MARTIN DE, SMITH P, GOILA-GAUR R etal.: Determinants of activity, invitro metabolism and invivo disposition of the novel maturation inhibitor PA-457. 11th Conference on Retroviruses and Opportunistic Infections. San Fransisco, CA, USA (2004):545.
   Google Scholar
• MARTIN DE, BALLOW CH, BLUM R etal.: The safety, tolerability and pharmacokinetics of PA-457, a first-in-class, HIV maturation inhibitor, in healthy volunteers. 7th International Congress on Drug Therapy for HIV Infection. Glasgow, UK (2004):P312.
   Google Scholar
• SMITH P, FORREST A, BEATTY G etal.: Pharmacokinetics/pharmacodynamics of PA-457 in a 10-day multiple dose monotherapy trial in HIV-infected patients. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA (2006):abstract 52.
   Google Scholar
• NOOR MA, FLINT OP, PARKER RA etal.: Evaluation of insulin sensitivity in healthy volunteers treated with low-dose ritonavir combined with atazanavir (ATV/RTV) or lopinavir (LPV/RTV): a prospective ransomised study using hyperinsulinaemic, euglycaemic clamp and oral glucose tolerance testing. 7th International Workshop on Adverse Drug Reactions and Liposytrophy. Dublin, Ireland (2005).
   Google Scholar